U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231744) titled 'Study of STLX-2012 in Healthy Volunteers' on Nov. 13.
Brief Summary: The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: STLX-2012
STLX-2012 IV
OTHER: Placebo
Placebo arm
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Stelexis BioSciences
Disclaimer: Curated by HT Syndication....